Actively Recruiting
Phase 2 Study of MK-5684 Compared to Standard Treatments for Breast, Ovarian, and Endometrial Cancers
Led by Merck Sharp & Dohme LLC · Updated on 2026-07-17
250
Participants Needed
58
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying MK-5684, a medicine designed to block steroid hormone production, to treat breast cancer, ovarian cancer, and endometrial cancer. The trial compares MK-5684 with standard treatments for these cancers to see if participants live longer without their cancer growing or spreading. The study is a Phase 2, open-label trial with multiple cancer types included. Participants with breast, ovarian, or endometrial cancer will be assigned to different treatment groups. Those with breast cancer receive MK-5684 plus corticosteroids or endocrine therapies like fulvestrant or exemestane. Ovarian cancer participants are observed without treatment during the study. Endometrial cancer participants receive one of several treatments chosen by their doctors, including megestrol acetate, tamoxifen, or letrozole. Treatments continue until reasons to stop arise. During the study, participants take oral medications and may receive injections depending on their group. Researchers monitor how long participants live without cancer progression, overall survival, response rates, and side effects. The study lasts up to about two years, with safety and treatment effects tracked throughout. Participants are regularly assessed for adverse events and treatment benefits to understand MK-5684s impact compared to other therapies.
CONDITIONS
Brief Title
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
Research Team
T
Toll Free Number
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
